-
公开(公告)号:US20110003757A1
公开(公告)日:2011-01-06
申请号:US12865634
申请日:2009-01-29
IPC分类号: A61K31/7004 , A61K31/7042 , A61P1/16
CPC分类号: C07D309/10 , C07D409/10 , C07H7/04 , C07H15/203 , C07H15/26
摘要: The present invention provides a pharmaceutical composition useful as a therapeutic agent for fatty liver disease. A pharmaceutical composition, which comprises (1S)-1,5-anhydro-1-[5-(azulen-2-ylmethyl)-2-hydroxyphenyl]-D-glucitol or a pharmaceutically acceptable salt thereof, (1S)-1,5-anhydro-1-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-D-glucitol or a pharmaceutically acceptable salt thereof, or alternatively, (1S)-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol or a pharmaceutically acceptable salt thereof, more specifically such a pharmaceutical composition for treating fatty liver disease, such as nonalcoholic fatty liver disease in one embodiment, or nonalcoholic simple fatty liver and/or nonalcoholic steatohepatitis in another embodiment.
摘要翻译: 本发明提供可用作脂肪肝病治疗剂的药物组合物。 一种药物组合物,其包含(1S)-1,5-脱水-1- [5-(薁-2-基甲基)-2-羟基苯基] -D-葡萄糖醇或其药学上可接受的盐,(1S)-1, 5-脱水-1- [3-(1-苯并噻吩-2-基甲基)-4-氟苯基] -D-葡萄糖醇或其药学上可接受的盐,或者,(1S)-1,5-脱水-1- [ 4-氯-3-(4-乙氧基苄基)苯基] -D-葡萄糖醇或其药学上可接受的盐,更具体地说,这种用于治疗脂肪肝疾病的药物组合物,例如在一个实施方案中的非酒精性脂肪肝疾病,或非酒精单纯脂肪 肝和/或非酒精性脂肪性肝炎。